- Home
- WXM vs LPCN Comparison
WXM vs LPCN Comparison
Compare WXM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WXM
- LPCN
- Stock Information
- Founded
- WXM 2009
- LPCN 1997
- Country
- WXM China
- LPCN United States
- Employees
- WXM N/A
- LPCN N/A
- Industry
- WXM
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- WXM
- LPCN Health Care
- Exchange
- WXM NYSE
- LPCN Nasdaq
- Market Cap
- WXM 15.3M
- LPCN 16.1M
- IPO Year
- WXM 2025
- LPCN N/A
- Fundamental
- Price
- WXM $2.20
- LPCN $3.20
- Analyst Decision
- WXM
- LPCN Strong Buy
- Analyst Count
- WXM 0
- LPCN 2
- Target Price
- WXM N/A
- LPCN $9.00
- AVG Volume (30 Days)
- WXM 100.6K
- LPCN 71.0K
- Earning Date
- WXM 01-01-0001
- LPCN 05-08-2025
- Dividend Yield
- WXM N/A
- LPCN N/A
- EPS Growth
- WXM 67.61
- LPCN N/A
- EPS
- WXM 0.18
- LPCN N/A
- Revenue
- WXM $15,524,259.00
- LPCN $3,674,834.00
- Revenue This Year
- WXM N/A
- LPCN N/A
- Revenue Next Year
- WXM N/A
- LPCN N/A
- P/E Ratio
- WXM $14.47
- LPCN N/A
- Revenue Growth
- WXM 10.86
- LPCN N/A
- 52 Week Low
- WXM $1.52
- LPCN $2.68
- 52 Week High
- WXM $7.99
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- WXM N/A
- LPCN 44.14
- Support Level
- WXM N/A
- LPCN $3.12
- Resistance Level
- WXM N/A
- LPCN $3.63
- Average True Range (ATR)
- WXM 0.00
- LPCN 0.41
- MACD
- WXM 0.00
- LPCN -0.04
- Stochastic Oscillator
- WXM 0.00
- LPCN 25.36
About WXM WF INTERNATIONAL LIMITED
WF International Ltd is engaged in the provision of supply, installation, fitting-out and maintenance services for HVAC system and floor heating systems. It provides the supply, installation and fitting-out services for HVAC systems for large-scaled commercial projects consisting of offices, hotels, manufactures, airports and hospitals, such as the International Finance Square HVAC projects across China, Chengdu Vanke Charm City, Chengdu Raffles Plaza, Chengdu Yinshi Plaza, Chengdu Metro No. Ten Line, and Panzhihua Jinhai Hotel.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.